Rivaset Uses
Was this medicine useful for you?
sponsored
Uses
Dosage
Side effects
Pregnancy
Overdose
Actions

What is Rivaset?

Rivaset patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease, or mild to moderate dementia associated with Parkinson's disease. Rivaset will not cure these diseases and it will not stop these diseases from getting worse. However, Rivaset can improve thinking ability in some patients with these diseases.

In Alzheimer's disease, many chemical changes take place in the brain. One of the earliest and biggest changes is that there is a decrease in a chemical called acetylcholine (ACh). ACh helps the brain to work properly. Rivaset is an acetylcholinesterase inhibitor. It slows the breakdown of ACh, so it can build up and have a greater effect. However, as Alzheimer's disease gets worse, there will be less and less ACh, so Rivaset may not work as well.

Rivaset is available only with your doctor's prescription.

Rivaset indications

sponsored

Alzheimer’s Disease

Rivaset transdermal system is indicated for the treatment of dementia of the Alzheimer’s type (AD). Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease.

Parkinson’s Disease Dementia

Rivaset transdermal system is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease (PDD).

How should I use Rivaset?

Use Rivaset solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Rivaset solution.

Uses of Rivaset in details

sponsored

Use: Labeled Indications

Alzheimer dementia:

Oral: Treatment of mild to moderate dementia of the Alzheimer type.

Transdermal: Treatment of mild, moderate, and severe dementia of the Alzheimer type.

Parkinson disease dementia: Treatment of mild to moderate dementia associated with Parkinson disease.

Off Label Uses

Dementia with Lewy bodies

Therapeutic options for the management of behavioral symptoms associated with Lewy body dementia are limited. Cholinesterase inhibitors are recommended for treatment of neuropsychiatric symptoms associated with Lewy body dementia by the Dementia with Lewy Bodies Consortium (McKeith 2005); however, Rivaset is the only cholinesterase inhibitor with placebo-controlled data supporting its use. Although limited to fewer than 200 patients, initial data indicate Rivaset provides statistically significant early improvement in clinical and cognitive assessments in patients with dementia with Lewy bodies and no deterioration with long-term therapy.

Rivaset description

sponsored

Each patch of 5 cm2 contains Rivastigmine base 9 mg, in vivo release rate of 4.6 mg/24 hrs.

Each patch of 10 cm2 contains Rivastigmine base 18 mg, in vivo release rate of 9.5 mg/24 hrs.

Rivaset patch also contains the following excipients: Vitamin E, poly (butyl methacrylate, methyl methacrylate), acrylic copolymer, silicone oil.

Each patch is a thin, matrix-type transdermal patch consisting of 3 layers. The outside of the backing layer is beige and labelled for each patch dose as follows: "Rivaset Patch 5" and "AMCX" or "Rivaset Patch 10" and "BHDI".

Rivaset dosage

Dosing In Alzheimer's Disease

Rivaset should be taken with meals in divided doses in the morning and evening.

The recommended dosage of Rivaset

Oral Solution and Capsules in Alzheimer's disease is 6 mg to 12 mg per day, administered twice a day (daily doses of 3 mg to 6 mg twice a day). There is evidence from the clinical trials that doses at the higher end of this range may be more beneficial.

Initial Dose

Initiate treatment with the 1.5 mg twice a day with Rivaset.

Dose Titration

After a minimum of 2 weeks and if well tolerated, increase the dose to 3 mg twice a day. Subsequent increases to 4.5 mg twice a day and 6 mg twice a day should be attempted after a minimum of 2 weeks at the previous dose and if well tolerated. The maximum dose is 6 mg twice a day (12 mg per day).

Dosing In Parkinson's Disease Dementia

Rivaset should be taken with meals in divided doses in the morning and evening.

The dosage of Rivaset shown to be effective in the single controlled clinical trial conducted in dementia associated with Parkinson's disease is 3 mg to 12 mg per day, administered twice a day (daily doses of 1.5 mg to 6 mg twice a day).

Initial Dose

Initiate treatment with the 1.5 mg twice a day with Rivaset.

Dose Titration

After a minimum of 4 weeks and if well tolerated, increase the dose to 3 mg twice a day. Subsequent increases to 4.5 mg twice a day and 6 mg twice a day should be attempted after a minimum of 4 weeks at the previous dose and if well tolerated. The maximum dose is 6 mg twice a day (12 mg per day).

Interruption Of Treatment

If adverse effects (e.g., nausea, vomiting, abdominal pain, loss of appetite) cause intolerance during treatment, the patient should be instructed to discontinue treatment for several doses and then restart at the same or next lower dose level.

If dosing is interrupted for 3 days or fewer, restart treatment with the same or lower dose of Rivaset. If dosing is interrupted for more than 3 days, treatment should be restarted with 1.5 mg twice a day and titrated as described above.

Dosing In Specific Populations

Dosing Modifications in Patients with Renal Impairment

Patients with moderate and severe renal impairment may be able to only tolerate lower doses.

Dosing Modifications in Patients with Hepatic Impairment

Patients with mild (Child-Pugh score 5 to 6) and moderate (Child-Pugh score 7 to 9) hepatic impairment may be able to only tolerate lower doses. No data are available on the use of Rivaset in patients with severe hepatic impairment.

Dosing Modifications in Patients with Low Body Weight

Carefully titrate and monitor patients with low body weight (less than 50 kg) for toxicities (e.g., excessive nausea, vomiting), and consider reducing the dose if such toxicities develop.

Important Administration Instructions

Caregivers should be instructed in the correct procedure for administering Rivaset

Oral Solution. In addition, they should be directed to the Instruction Sheet (included with the product) describing how the solution is to be administered. Caregivers should direct questions about the administration of the solution to either their physician or pharmacist.

Patients should be instructed to remove the oral dosing syringe provided in its protective case, and using the provided syringe, withdraw the prescribed amount of Rivaset

Oral Solution from the container. Each dose of Rivaset

Oral Solution may be swallowed directly from the syringe or first mixed with a small glass of water, cold fruit juice, or soda. Patients should be instructed to stir and drink the mixture.

Rivaset

Oral Solution and Rivaset Capsules may be interchanged at equal doses.

How supplied

Dosage Forms And Strengths

Rivaset Capsules

Capsules, containing Rivaset tartrate equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of Rivaset base, are available as follows:

1.5 mg capsule – yellow, “Rivaset 1,5 mg” is printed in red on the body of the capsule.

3 mg capsule – orange, “Rivaset 3 mg” is printed in red on the body of the capsule.

4.5 mg capsule – red, “Rivaset 4,5 mg” is printed in white on the body of the capsule.

6 mg capsule – orange and red, “Rivaset 6 mg” is printed in red on the body of the capsule.

Rivaset

Oral Solution

Oral Solution is a clear yellow, solution containing Rivaset tartrate equivalent to 2 mg/mL of Rivaset base. For a full list of excipients, see DESCRIPTION.

Storage And Handling

Rivaset Capsules

Rivaset (Rivaset tartrate) Capsules equivalent to 1.5 mg, 3 mg, 4.5 mg, or 6 mg of Rivaset base are available as follows:

1.5 mg capsule – yellow, “Rivaset 1,5 mg” is printed in red on the body of the capsule.

Bottles of 60 NDC 0078-0323-44

Bottles of 500 NDC 0078-0323-08

Unit Dose (blister pack) Box of 100 (strips of 10) NDC 0078-0323-06

3 mg capsule – orange, “Rivaset 3 mg” is printed in red on the body of the capsule.

Bottles of 60 NDC 0078-0324-44

Bottles of 500 NDC 0078-0324-08

Unit Dose (blister pack) Box of 100 (strips of 10) NDC 0078-0324-06

4.5 mg capsule – red, “Rivaset 4,5 mg” is printed in white on the body of the capsule.

Bottles of 60 NDC 0078-0325-44

Bottles of 500 NDC 0078-0325-08

Unit Dose (blister pack) Box of 100 (strips of 10) NDC 0078-0325-06

6 mg capsule – orange and red, “Rivaset 6 mg” is printed in red on the body of the capsule.

Bottles of 60 NDC 0078-0326-44

Bottles of 500 NDC 0078-0326-08

Unit Dose (blister pack) Box of 100 (strips of 10) NDC 0078-0326-06

Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F). Store in a tight container.

Rivaset

Oral Solution

Rivaset (Rivaset tartrate)

Oral Solution

is supplied as 120 mL of a clear, yellow solution (2 mg/mL base) in a 4ounce USP Type III amber glass bottle with a child-resistant 19-mm linerless cap, dip tube and self-aligning plug. The oral solution is packaged with a dispenser set which consists of an assembled oral dosing syringe that allows dispensing a maximum volume of 3 mL corresponding to a 6-mg dose, with a plastic tube container.

Bottles of 120 mL NDC 0078-0339-31

Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F). Store in an upright position and protect from freezing.

When Rivaset

Oral Solution is combined with cold fruit juice or soda, the mixture is stable at room temperature for up to 4 hours.

Distributed by: Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936. Revised: Oct 2013

Rivaset interactions

See also:
What other drugs will affect Rivaset?

sponsored

Rivaset is metabolized mainly through hydrolysis by esterases. Minimal metabolism occurs via the major cytochrome P-450 isoenzymes. Thus, no pharmacokinetic interactions are anticipated with other drugs metabolized by these enzymes.

No pharmacokinetic interaction was observed between oral Rivaset and digoxin, warfarin, diazepam or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is not affected by administration of Rivaset. No untoward effects on cardiac conduction were observed following concomitant administration of digoxin and Rivaset.

Concomitant administration of Rivaset with commonly prescribed medications eg, antacids, antiemetics, antidiabetics, centrally-acting antihypertensives, β-blockers, calcium channel blockers, inotropic drugs, antianginals, nonsteroidal anti-inflammatory drugs, estrogens, analgesics, benzodiazepines and antihistamines, was not associated with an alteration in the kinetics of Rivaset, or an increased risk of clinically relevant untoward effects.

In view of its pharmacodynamic effects, Rivaset should not be given concomitantly with other cholinomimetic drugs and might interfere with the activity of anticholinergic medications.

As a cholinesterase inhibitor, Rivaset may exaggerate the effects of succinylcholine-type muscle relaxants during anesthesia.

Incompatibilities: Not applicable.

Rivaset side effects

See also:
What are the possible side effects of Rivaset?

The following adverse reactions are described below and elsewhere in the labeling:

•
Gastrointestinal Adverse Reactions.
•
Skin Reactions.
•
Other Adverse Reactions from Increased Cholinergic Activity.

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Rivaset transdermal system has been administered to 4516 patients with Alzheimer’s disease during clinical trials worldwide. Of these, 3005 patients have been treated for at least 26 weeks, 1771 patients have been treated for at least 52 weeks, 974 patients have been treated for at least 78 weeks and 24 patients have been treated for at least 104 weeks.

Mild to Moderate Alzheimer’s Disease

24-Week International Placebo-Controlled Trial (Study 1)

Most Common Adverse Reactions

The most common adverse reactions in patients administered Rivaset transdermal system in Study 1, defined as those occurring at a frequency of at least 5% in the 9.5 mg/24 hours Rivaset transdermal system arm and at a frequency at higher than in the placebo group, were nausea, vomiting, and diarrhea. These reactions were dose-related, with each being more common in patients using the unapproved 17.4 mg/24 hours Rivaset transdermal system than in those using the 9.5 mg/24 hours Rivaset transdermal system.

Discontinuation Rates

In Study 1, which randomized a total of 1195 patients, the proportions of patients in the Rivaset transdermal system 9.5 mg/24 hours, Rivaset tartrate capsules 6 mg twice daily, and placebo groups who discontinued treatment due to adverse events were 10%, 8%, and 5%, respectively.

The most common adverse reactions in the Rivaset transdermal system-treated groups that led to treatment discontinuation in this study were nausea and vomiting. The proportions of patients who discontinued treatment due to nausea were 0.7%, 1.7%, and 1.3% in the Rivaset transdermal system 9.5 mg/24 hours, Rivaset tartrate capsules 6 mg twice daily, and placebo groups, respectively. The proportions of patients who discontinued treatment due to vomiting were 0%, 2.0%, and 0.3% in the Rivaset transdermal system 9.5 mg/24 hours, Rivaset tartrate capsules 6 mg twice daily, and placebo groups, respectively.

Adverse Reactions Observed at an Incidence of ≥2%

Table 1 lists adverse reactions seen at an incidence of ≥2% in either Rivaset transdermal system-treated group in Study 1 and for which the rate of occurrence was greater for patients treated with that dose of Rivaset transdermal system than for those treated with placebo. The unapproved 17.4 mg/24 hours Rivaset transdermal system arm is included to demonstrate the increased rates of gastrointestinal adverse reactions over those seen with the 9.5 mg/24 hours Rivaset transdermal system.

*Vomiting was severe in 0% of patients who received Rivaset transdermal system 9.5 mg/24 hours, 1% of patients who received Rivaset transdermal system 17.4 mg/24 hours, 1% of patients who received the Rivaset tartrate capsule at doses up to 6 mg twice daily, and 0% of those who received placebo.

**Weight Decreased as presented in Table 1 is based upon clinical observations and/or adverse events reported by patients or caregivers. Body weight was also monitored at prespecified time points throughout the course of the clinical study. The proportion of patients who had weight loss equal to or greater than 7% of their baseline weight was 8% of those treated with Rivaset transdermal system 9.5 mg/24 hours, 12% of those treated with Rivaset transdermal system 17.4 mg/24 hours, 11% of patients who received the Rivaset tartrate capsule at doses up to 6 mg twice daily and 6% of those who received placebo. It is not clear how much of the weight loss was associated with anorexia, nausea, vomiting, and the diarrhea associated with the drug.

48-Week International Active Comparator-Controlled Trial (Study 2)

Most Common Adverse Reactions

In Study 2 of the commonly observed adverse reactions (≥3% in any treatment group) the most frequent event in the Rivaset transdermal system 13.3 mg/24 hours group was nausea, followed by vomiting, fall, weight decreased, application site erythema, decreased appetite, diarrhea and urinary tract infection (Table 3). The percentage of patients with these events was higher in the Rivaset transdermal system 13.3 mg/24 hours group than in the Rivaset transdermal system 9.5 mg/24 hours group. Patients with nausea, vomiting, diarrhea and decreased appetite experienced these reactions more often during the first 4 weeks of the double-blind treatment phase. These reactions decreased over time in each treatment group. Weight decreased was reported to have increased over time in each treatment group.

Discontinuation Rates

Table 2 displays the most common adverse reactions leading to discontinuation during the 48-week, double-blind treatment phase in Study 2.

Most Common Adverse Reactions ≥3%

Other adverse reactions of interest which occurred less frequently, but which were observed in a markedly higher percentage of patients in the Rivaset transdermal system 13.3 mg/24 hours group than in the Rivaset transdermal system 9.5 mg/24 hours group in Study 2, included dizziness and upper abdominal pain. The percentage of patients with these reactions decreased over time in each treatment group (Table 3). The adverse reaction severity profile was generally similar for both the Rivaset transdermal system 13.3 mg/24 hours and 9.5 mg/24 hours groups.

*Decreased Weight as presented in Table 3 is based upon clinical observations and/or adverse events reported by patients or caregivers. Body weight was monitored as a vital sign at pre-specified time points throughout the course of the clinical study. The proportion of patients who had weight loss equal to or greater than 7% of their baseline weight was 15.2% of those treated with Rivaset transdermal system 9.5 mg/24 hours and 18.6% of those treated with Rivaset transdermal system 13.3 mg/24 hours during the 48-week double-blind treatment period.

Severe Alzheimer’s Disease

24-Week US Controlled Trial (Study 3)

Most Commonly Observed Adverse Reactions

The most common adverse reactions in patients administered Rivaset transdermal system in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the 13.3 mg/24 hours Rivaset transdermal system arm and at a frequency higher than in the 4.6 mg/24 hours Rivaset transdermal system were application site erythema, fall, insomnia, vomiting, diarrhea, weight decreased, and nausea (Table 4). Patients in the lower dose group reported more events of agitation, urinary tract infection, and hallucinations than patients in the higher dose group.

Discontinuation Rates

In Study 3, the proportions of patients in the Rivaset transdermal system 13.3 mg/24 hours (n=355) and Rivaset transdermal system 4.6 mg/24 hours (n=359), who discontinued treatment due to adverse reactions were 21% and 14%, respectively.

The most frequent adverse reaction leading to discontinuation in the 13.3 mg/24 hours treatment group versus the 4.6 mg/24 hours treatment group was agitation (2.8% versus 2.2%), followed by vomiting (2.5% and 1.1%), nausea (1.7% and 1.1%), decreased appetite (1.7% and 0%), aggression (1.1% and 0.3%), fall (1.1% and 0.3%) and syncope (1.1% and 0.3%). Otherwise, all AEs leading to discontinuation were reported in <1% of patients.

Most Commonly Observed Adverse Reactions ≥5%

Other adverse reactions of interest which were observed in a higher percentage of patients in the Rivaset transdermal system 13.3 mg/24 hours group than in the Rivaset transdermal system 4.6 mg/24 hours group, included application site erythema, fall, insomnia, vomiting, diarrhea, weight decreased, and nausea (Table 4). Overall, the majority of patients in this study experienced adverse reactions that were mild (30.7%) or moderate (32.1%) in severity. Slightly more patients in the 4.6 mg/24 hours patch group reported mild events than in the 13.3 mg/24 hours patch group, while the numbers of patients reporting moderate events were comparable between groups. Severe adverse reactions were reported at a slightly higher percentage at the higher dose (12.4%) than at the lower dose (10%) treatment groups. With the exception of severe adverse reactions of agitation (13.3 mg: 1.1%; 4.6 mg: 1.4%), fall (13.3 mg: 1.1%) and urinary tract infection (4.6 mg: 1.1%), all adverse reactions reported as severe occurred in less than 1% of patients in either treatment group.

Application Site Reactions

Application site skin reactions leading to discontinuation were observed in ≤2.3% of Rivaset transdermal system patients. This number was 4.9% and 8.4% in the Chinese population and Japanese population, respectively.

Cases of skin irritation were captured separately on an investigator-rated skin irritation scale. Skin irritation, when observed, was mostly slight or mild in severity and was rated as severe in ≤2.2% of Rivaset transdermal system patients in a double-blind controlled study and in ≤3.7% of Rivaset transdermal system patients in a double-blind controlled study in Japanese patients.

Parkinson’s Disease Dementia

76-week International Open-Label Trial (Study 4)

Rivaset transdermal system has been administered to 288 patients with mild to moderate Parkinson’s Disease Dementia in a single, 76-week, open-label, active-comparator safety study. Of these, 256 have been treated for at least 12 weeks, 232 for at least 24 weeks, and 196 for at least 52 weeks.

Treatment with Rivaset transdermal system was initiated at 4.6 mg/24 hours and if tolerated the dose was increased after 4 weeks to 9.5 mg/24 hours. Rivaset tartrate capsule (target maintenance dose of 12 mg/day) served as the active comparator and was administered to 294 patients. Adverse reactions are presented in Table 5.

Additional adverse reactions observed during the 76-week prospective, open-label study in patients with dementia associated with Parkinson’s disease treated with Rivaset transdermal system: Frequent (those occurring in at least 1/100 patients): dehydration, weight decreased, aggression, hallucination visual.

In patients with dementia associated with Parkinson’s disease the following adverse drug reactions have only been observed in clinical trials with Rivaset tartrate capsules: Frequent: nausea, vomiting, decreased appetite, restlessness, worsening of Parkinson’s disease, bradycardia, diarrhea, dyspepsia, salivary hypersecretion, sweating increased; Infrequent (those occurring between 1/100 to 1/1000 patients): dystonia, atrial fibrillation, atrioventricular block.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of Rivaset. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypertension, application site hypersensitivity, urticaria, blister, allergic dermatitis, seizure, Parkinson’s disease (worsening), tachycardia, abnormal liver function tests, disseminated allergic dermatitis, and tremor.

Rivaset contraindications

See also:
What is the most important information I should know about Rivaset?

Before taking Rivaset, tell your doctor if you have a heart rhythm disorder such as "sick sinus syndrome" (slow heartbeats), an enlarged prostate, urination problems, asthma, obstructive pulmonary disease, or a seizure disorder such as epilepsy.

Stop using Rivaset and call your doctor at once if the medicine causes you to have stomach pain, nausea and vomiting, and loss of appetite.

This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

It is important to use Rivaset regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.

If you stop taking Rivaset for any reason, do not restart the medication without talking to your doctor first. You may need to restart treatment with a lower dose.

If you need to have any type of surgery, tell the surgeon ahead of time that you are taking Rivaset.

Rivaset can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.



Active ingredient matches for Rivaset:

Rivastigmine in Greece.


List of Rivaset substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Rivaron (South Korea)
Rivasmina (Argentina)
RIVASMINE (India)
RIVASMINE Capsule/ Tablet / 1.5mg / 10 units (Cipla)$ 0.54
RIVASMINE Capsule/ Tablet / 3mg / 10 units (Cipla)$ 0.78
RIVASMINE Capsule/ Tablet / 4.5mg / 10 units (Cipla)$ 1.02
RIVASMINE Capsule/ Tablet / 6mg / 10 units (Cipla)$ 1.27
Rivasmine 1.5mg CAP / 10 (Cipla)$ 0.54
Rivasmine 3mg CAP / 10 (Cipla)$ 0.78
Rivasmine 4.5mg CAP / 10 (Cipla)$ 1.02
Rivasmine 6mg CAP / 10 (Cipla)$ 1.27
1.5 mg x 10's (Cipla)$ 0.54
3 mg x 10's (Cipla)$ 0.78
4.5 mg x 10's (Cipla)$ 1.02
6 mg x 10's (Cipla)$ 1.27
RIVASMINE 1.5 MG CAPSULE 1 strip / 10 capsules each (Cipla)$ 0.56
RIVASMINE 3 MG CAPSULE 1 strip / 10 capsules each (Cipla)$ 0.78
RIVASMINE 4.5 MG CAPSULE 1 strip / 10 capsules each (Cipla)$ 1.02
RIVASMINE 6 MG CAPSULE 1 strip / 10 capsules each (Cipla)$ 1.30
RIVASMINE cap 1.5 mg x 10's (Cipla)$ 0.54
RIVASMINE cap 3 mg x 10's (Cipla)$ 0.78
RIVASMINE cap 4.5 mg x 10's (Cipla)$ 1.02
RIVASMINE cap 6 mg x 10's (Cipla)$ 1.27
Rivasmine 1.5mg CAP / 10 (Cipla)$ 0.54
Rivasmine 3mg CAP / 10 (Cipla)$ 0.78
Rivasmine 4.5mg CAP / 10 (Cipla)$ 1.02
Rivasmine 6mg CAP / 10 (Cipla)$ 1.27
Rivasmine 1.5mg Capsule (Cipla)$ 0.06
Rivasmine 3mg Capsule (Cipla)$ 0.08
Rivasmine 4.5mg Capsule (Cipla)$ 0.10
Rivasmine 6mg Capsule (Cipla)$ 0.13
Rivast (Taiwan)
Rivast 2 mg/1 mL x 120 mL
Rivasta (Thailand)
Rivasta cap 1.5 mg 10 x 10's (Siam Bheasach)
Rivasta cap 3 mg 10 x 10's (Siam Bheasach)
Rivastach (Japan)
Rivastigmelon (Australia)
Rivastigmin +pharma (Czech Republic)
Rivastigmin - 1 A Pharma (Germany)
Rivastigmin AbZ (Germany)
Rivastigmin Actavis (Austria)
Rivastigmin Actavis 1,5 mg (Austria)
Rivastigmin Actavis 3 mg (Austria)
Rivastigmin Actavis 4,5 mg (Austria)

See 550 substitutes for Rivaset

References

  1. DailyMed. "RIVASTIGMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "rivastigmine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "rivastigmine". http://www.drugbank.ca/drugs/DB00989 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Rivaset are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Rivaset. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 17 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

More about Rivaset

  • Rivaset generic and brand names

    • Clinician Information

  • Administration
  • Breastfeeding
  • Contraindications
  • Interactions
  • Pharmacology
  • Precautions
  • Warnings

    • Share on Facebook Tweet

    | Privacy Policy
    This site does not supply any medicines. It contains prices for information purposes only.
    © 2003 - 2024 ndrugs.com All Rights Reserved